MX2021011610A - Combinaciones de iadademstat para terapia contra el cancer. - Google Patents

Combinaciones de iadademstat para terapia contra el cancer.

Info

Publication number
MX2021011610A
MX2021011610A MX2021011610A MX2021011610A MX2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A MX 2021011610 A MX2021011610 A MX 2021011610A
Authority
MX
Mexico
Prior art keywords
iadademstat
combinations
cancer therapy
cancer
inhibitor
Prior art date
Application number
MX2021011610A
Other languages
English (en)
Spanish (es)
Inventor
Filippo Ciceri
Original Assignee
Oryzon Genomics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oryzon Genomics Sa filed Critical Oryzon Genomics Sa
Publication of MX2021011610A publication Critical patent/MX2021011610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021011610A 2019-03-25 2020-03-25 Combinaciones de iadademstat para terapia contra el cancer. MX2021011610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382206 2019-03-25
PCT/EP2020/058362 WO2020193631A1 (en) 2019-03-25 2020-03-25 Combinations of iadademstat for cancer therapy

Publications (1)

Publication Number Publication Date
MX2021011610A true MX2021011610A (es) 2021-10-13

Family

ID=66175363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011610A MX2021011610A (es) 2019-03-25 2020-03-25 Combinaciones de iadademstat para terapia contra el cancer.

Country Status (13)

Country Link
US (1) US20220175698A1 (cg-RX-API-DMAC7.html)
EP (1) EP3946295B1 (cg-RX-API-DMAC7.html)
JP (2) JP7824627B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210142614A (cg-RX-API-DMAC7.html)
CN (2) CN113573702A (cg-RX-API-DMAC7.html)
AU (1) AU2020249493B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016171A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132473A1 (cg-RX-API-DMAC7.html)
IL (1) IL286353A (cg-RX-API-DMAC7.html)
MX (1) MX2021011610A (cg-RX-API-DMAC7.html)
PH (1) PH12021552326A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109025XA (cg-RX-API-DMAC7.html)
WO (1) WO2020193631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9469597B2 (en) 2011-10-20 2016-10-18 Oryzon Genomics S.A. (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
EP3090998A1 (en) 2015-05-06 2016-11-09 F. Hoffmann-La Roche AG Solid forms
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
US20190256929A1 (en) * 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy

Also Published As

Publication number Publication date
CN113573702A (zh) 2021-10-29
JP7824627B2 (ja) 2026-03-05
SG11202109025XA (en) 2021-09-29
JP2026077769A (ja) 2026-05-13
KR20210142614A (ko) 2021-11-25
AU2020249493A1 (en) 2021-09-16
PH12021552326A1 (en) 2022-06-27
JP2022526525A (ja) 2022-05-25
EP3946295A1 (en) 2022-02-09
BR112021016171A2 (pt) 2021-10-05
CA3132473A1 (en) 2020-10-01
CN121422229A (zh) 2026-01-30
US20220175698A1 (en) 2022-06-09
WO2020193631A1 (en) 2020-10-01
EP3946295B1 (en) 2026-08-05
AU2020249493B2 (en) 2025-08-28
IL286353A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
MY208549A (en) Parp1 inhibitors
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2019001920A (es) Arn la terapia contra el cancer.
SG10201902664RA (en) Combination therapy for treating cancer
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MY209035A (en) Tricyclic compounds and their use
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12022550130A1 (en) Enzyme inhibitors
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2020011817A (es) Metodos para tratar el linfoma.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX2026002367A (es) Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso
MX2024002069A (es) Anticuerpos anti-hla-g.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY200161A (en) Bacteria for targeting tumors and treating cancer
EA202193111A1 (ru) Композиции и способы для лечения рака